There are no Focus articles on RHHVF.
There are no Related articles on RHHVF.
There are no News articles on RHHVF.
Wed, Jul. 2, 2:36 AM
- Roche (RHHBY) has announced it will buy Seragon, a breast cancer research company, for $725M. The company may pay up to another $1B based on future performance. Seragon was spun out from Aragon Pharmaceuticals last year, when the latter was purchased for $650M by Johnson & Johnson.
- Seragon is the second major acquisition for Roche in the last two months. The company bought Genia Technologies for up to $350M in in June.
Mar. 3, 2013, 3:47 AMThe Swiss are voting in a referendum today on an "anti-fat cat" initiative that would allow investors to hold binding votes on executive pay at listed companies and allow them to block large payouts at the start or end of a manager's employment. The measure is expected to pass. Companies that will be affected include Novartis (NVS), Nestle, UBS, Credit Suisse (CS), ABB, Roche, Transocean (RIG) and Weatherford (WFT). | 13 Comments
Feb. 17, 2013, 5:32 AMAbbVie (ABBV) and Roche (RHHBY.OB) have halted five studies of their ABT-199 drug for leukemia and lymphoma after two patients died of tumor lysis syndrome, when the rapid destruction of malignant cells causes acute kidney failure. The firms are working to refine the dose to overcome the problem and hopes to start Phase III testing of ABT-199 this year, as planned. | 2 Comments
Oct. 24, 2012, 5:02 AMThe European Medicines Agency yesterday said it's launching an infringement procedure against Roche (RHHBY.OB) for not properly looking into 80,000 reports of issues received from U.S. patients and doctors relating to 19 of the company's drugs, including best-sellers Herceptin and Avastin. If found guilty of wrongdoing, Roche could face a fine of up to 5% of its annual revenues. | Comment!
Oct. 16, 2012, 3:09 AMRoche Holdings (RHHBF.PK): Q3 revenues +15% to 11.27B francs ($12.07B) vs consensus of 11.12B francs. Doesn't provide profit figures. Sales boosted by a weaker franc and growth in cancer medicines, although eye drug Lucentis declined due to competition. Reiterates FY outlook: sales growth in low-to-mid single digits, core earnings in high single-digits. Roche still wants to expand in gene sequencing despite failure of Illumina bid and is looking at deals. (PR) | Comment!
Sep. 19, 2012, 4:23 AMIllumina (ILMN) CEO Jay Flatley tells Bloomberg that while the fiscal cliff will affect a third of the gene-sequencing company's customers, "it's going to probably be pretty short-lived." Flatley also says that Roche going public in January with its $6.7B offer for Illumina stopped the board from properly discussing the offer and possibly put paid to the deal. | 2 Comments
Aug. 27, 2012, 8:26 AMRoche's (RHHBY.OB) breast cancer drug T-DM1 "significantly" extended the lives of patients in a Phase III trial, a precondition for European regulators approving the treatment. Roche is developing T-DM1 with technology it has licensed from ImmunoGen (IMGN), which is rocketing 17.05% premarket. An analyst estimates that peak sales of T-DM1 could reach 1.6B Swiss francs ($1.67B). (PR) | Comment!
Jul. 25, 2012, 10:35 AMMore on Regeneron (REGN) Q2: swings to net profit of $76.7M from loss of $62.5M last year, boosted by sales of its Eylea eye treatment, which surged 57% Q/Q to $194M. Increases FY Eylea sales forecast for the 3rd time, now expecting $700M-$750M vs. $500M-$550M previously. Eylea taking market share from Roche's Lucentis and off-label Avastin. Shares +3.85%. | Comment!
There are no StockTalks on this stock yet.
RHHVF vs. ETF Alternatives
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and... More
Other News & PR